FDA Steps Up Alzheimer’s Initiatives, Plans October Stakeholders Meeting

Drug treatments and biomarker development for Alzheimer's disease are on the agenda of a meeting FDA expects to hold in October with neurology organizations, Janet Woodcock, the agency's chief medical officer, said during a July 25 audio conference sponsored by Avalere